Kevin Gorman, Neurocrine Biosciences CEO

Neu­ro­crine’s de­pres­sion drug pass­es Phase 2 tri­al

Neu­ro­crine Bio­sciences re­port­ed that its pill for ma­jor de­pres­sive dis­or­der re­duced scores on a de­pres­sion sever­i­ty scale at about one month in a Phase 2 tri­al.

In the SAV­IT­RI study, 183 adult par­tic­i­pants were as­signed ei­ther Neu­ro­crine’s treat­ment, known as NBI-1065845, or a place­bo tablet.

Pa­tients who re­ceived Neu­ro­crine’s pill saw a sta­tis­ti­cal­ly sig­nif­i­cant re­duc­tion in their scores com­pared to base­line on the Mont­gomery-Ås­berg De­pres­sion Rat­ing Scale at both 28 days and 56 days, meet­ing the pri­ma­ry and key sec­ondary end­points, re­spec­tive­ly, in the mid-stage study.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.